Zero-order Delivery of Alfuzosin Hydrochloride with Hydrophilic Polymers |
Park, Jun-Bom
(College of Pharmacy, Sahm Yook University)
Hwang, Chang-Hwan (College of Pharmacy, Sahm Yook University) Noh, Hyung-Gon (College of Pharmacy, Sahm Yook University) Chae, Yu-Byeong (College of Pharmacy, Sahm Yook University) Song, Jun-Woo (College of Pharmacy, Sahm Yook University) Kang, Chin-Yang (College of Pharmacy, Sahm Yook University) |
1 | Bourne DWA, 2002. Pharmacokinetics. In: Banker G.S., Rhodes C.T., Modern Pharmaceutics, 4th ed., marcel Dekker Inc., New York, 67-92. |
2 | Buzelin, J.M., Hebert, M., Blondin, P., te Prazalf Group, 1993. Alpha blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin, Br. J. Urol. 72, 922-927. DOI |
3 | Costa, P., Lobo, J., 2001. Modeling and comparison of dissolution profile, Eur. J. Pharm. 13, 123-133. DOI |
4 | Hadjiioannou, T.P., Christian, G.D., Koupparis, M.A., Macheras, P.E., 1993. Quantitative Calculations in Pharmaceutical Practice and Reserarch, VCH Publishers inc., New York, 345-348. |
5 | Higuchi, T., 1963. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm.Sci., 52, 1145-1149. DOI |
6 | Hixson, A.W., Crowell, J.H., 1931. Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind. Eng. Chem., 23, 923-931. DOI |
7 | Vueba, M.L., Batista, de Carvalho, L.A.E., Veiga, F., Sousa, J.J., Pina, M.E., 2004. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets, Eur. J. Pharm. Biopharm. 58, 51-59. DOI |
8 | Jardin, A.H., Bensadoun, H., Delauche-Cavaller, M.C.., Attali, P., The BPH-ALF Group, 1991. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337, 1457-1461. DOI |
9 | Jardin, A.H., Bensadoun, H., Delauche-Cavaller, M.C., Attali, P., The BPH-ALF Group, 1993. Long term treatment of benign prostatic hypertropy with alfuzosin: a 12-18 month assessment. ., 72, 615-620. DOI |
10 | Jardin, A.H., Bensadoun, H., Delauche-Cavaller, M.C., Attali, P., The BPH-ALF Group, 1999. Long term treatment of benign prostatic hypertropy with alfuzosin: a 24-30 month survey. Br. J. Urol. 74, 579-584. DOI |
11 | JENN-CHIANG MACHINERY Homepage http://www.jcmco.com.tw/ dh.htm |
12 | Korsmeyer, R.W., Gurny, R., Doelker, E., Buri, P., Peppas, N.A., 1983. Mechanisms of solute release from porous hydrophilic polymers. Int. J. pharm., 15, 25-35. DOI |
13 | Maggi, L., Conte, U., Grenier, P., Vergnault, G., Dufour, A., Jarreau, F.X., Rauch-Desant, C., 2000. Tablet with controlled release of alfuzosine chlorhydrate, US Patent 6, 149,940. |
14 | Moore, J.W., Flanner, H.H., 1996. Mathematical comparison of dissolution profile, Pharm. Tech. 20, 64-74. |
15 | Shoaib, M.H., Tazeen, J., Merchant, H.A., Yousuf, R.I., 2006. Evaluation of drug release kinetics from Ibuprofen matrix tablet using HPMC. Pak. J. Pharm. Sci., 19, 119-124. |
16 | Tahara, K., Yamamoto, K., Nishihata, T., 1995. Overall mechanism behind matrix sustained release (SR) tablet prepared with hydroxypropyl methylcellulose 2910, J. Control. Release 35, 59-66. DOI |
17 | Teillac, P., Delauche-Cavallier, M.C., Attali, P., The Dualf Group, 1992. Urinary flow assessment after a single oral administration of alfuzosin, a new alpha1, blocker, in patients with benign prostatic hypertrophy, Br. J. Urol. 70, 58-64. DOI |